Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of LYNC-101 in Healthy Adult Participants
NCT07505030Phase 1Enrolling by invitation
- Sponsor
- LyncBio Therapeutics Inc.
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LYNC-101 in ulcerative colitis (UC) (7 arms), sponsored by LyncBio Therapeutics Inc. Primary endpoints: Incidence and severity of adverse events, serious adverse events, and treatment-emergent adverse events up to 85 days, Changes in 12-lead electrocardiogram parameters up to 85 days and 3 more. Started May 2026; status: enrolling by invitation.
02
Drugs
LYNC-101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07505030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505030.